✦ LIBER ✦

Elevated expression of CXC chemokines in pediatric osteosarcoma patients

✍ Scribed by Yiting Li; Ricardo Flores; Alexander Yu; M. Fatih Okcu; Jeffrey Murray; Murali Chintagumpala; John Hicks; Ching C. Lau; Tsz-Kwong Man

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 427 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25563

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Expression of major vault protein gene i

Expression of major vault protein gene in osteosarcoma patients

✍ Cristiane Arruda Dalla-Torre; Silvia Regina Caminada de Toledo; Maisa Yoshimoto; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 120 KB

## Abstract Osteosarcoma (OS) is a primary malignant tumor of bone. Despite the successful use of multiple chemotherapeutic agents in the treatment of OS, more than 30% of OS tumors remain resistant to treatment. Elucidation of cellular resistance mechanisms may lead to better treatments for cancer

Reduced expression of the CXC chemokine

Reduced expression of the CXC chemokine hIRH/SDF-1α mRNA in hepatoma and digestive tract cancer

✍ Kenji Shibuta; Nasim Ara Begum; Masaki Mori; Katsuhiro Shimoda; Tsuyoshi Akiyosh 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 162 KB 👁 1 views

We isolated human intercrine reduced in hepatomas (hIRH) as a mRNA whose expression was reduced in differential displays from human hepatocellular carcinoma. hIRH is equivalent to the ␣-chemokine SDF-1␣/PBSF. We have previously demonstrated on Northern blot analysis that although hIRH mRNA expressio

Chemokine receptor expression on dendrit

Chemokine receptor expression on dendritic cells is normal in HIV-infected patients with a stable response to art, but chemokine levels remain elevated

✍ Silvia Lee; Sonia Fernandez; Martyn French; Patricia Price 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

## Abstract The development of strategies to optimize T‐cell responses in previously immunodeficient HIV patients with a stable virological response to ART requires an understanding of the factors that affect responsiveness. Chemokines direct the migration of dendritic cells (DC) to non‐lymphoid ti

Association between lack of angiogenic r

Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: Possible link to vasculopathy

✍ Ndate Fall; Kevin E. Bove; Keith Stringer; Daniel J. Lovell; Hermine I. Brunner; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 2 views

## Abstract ## Objective To investigate the relationship between the vasculopathy of juvenile dermatomyositis (juvenile DM) and the balance between the angiostatic ELR− and angiogenic ELR+ CXC chemokines in the muscle of patients with the disease. ## Methods The expression of 3 ELR− CXC chemokin

Treatment of osteosarcoma with ifosfamid

Treatment of osteosarcoma with ifosfamide: Comparison of response in pediatric patients with recurrent disease versus patients previously untreated: A pediatric oncology group study

✍ Harris, Michael B. ;Cantor, Alan B. ;Goorin, Allen M. ;Shochat, Stephen J. ;Ayal 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 523 KB

## Abstract This study was designed to test if the activity of a phase II agent, ifosfamide, would have been underestimated if it was tested exclusively in a population of children and young adults with recurrent osteosarcoma. The response rate to ifosfamide was compared in patients younger than 30

Loss of p16INK4a expression correlates w

Loss of p16INK4a expression correlates with decreased survival in pediatric osteosarcomas

✍ Anirban Maitra; Helen Roberts; Arthur G. Weinberg; Joseph Geradts 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 348 KB 👁 1 views

## Abnormalities of the G 1 cell-cycle checkpoint are commonly reported in cancers at various anatomic sites. pRB, p16 INK4a and cyclin D1 are critical G 1 -checkpoint proteins responsible for maintaining the balance of cellular proliferation. We examined a series of 38 pediatric osteosarcomas for